BioXcel Execs Face Investor Suit Over Alzheimer's Drug Probe
Top brass at artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. have been hit with a shareholder derivative suit alleging they took too long to disclose a U.S. Food and Drug Administration...To view the full article, register now.
Already a subscriber? Click here to view full article